The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Background: The ability to automatically transfer data to clinicians and receive timely guidance in therapy adjustments through remote and in-office consults can positively impact patients' perceptions about quality of care, which is positively associated with clinical outcomes. We assessed the impact of using the Accu-Chek Connect diabetes management system on treatment satisfaction, diabetes distress, and glycemic control in adults with type 1 diabetes and insulin-treated type 2 diabetes.
Accu-chek 360 Diabetes Management System Download
Download File 🔥 https://urluso.com/2yGav0 🔥
Subjects and methods: This 6-month, prospective, multicenter, single-arm study assessed the impact of using the system on treatment satisfaction and glycemic control among 87 adults with insulin-treated diabetes (multiple daily insulin injections and basal only), with 8.8% 1.6% glycated hemoglobin (HbA1c) at baseline. The Diabetes Treatment Satisfaction Questionnaire-status (DTSQs) and Diabetes Distress Scale (DDS) were administered at baseline, and the Diabetes Treatment Satisfaction Questionnaire-change (DTSQc) and DDS at 6 months. Changes in HbA1c, average blood glucose (BG), and other metrics were also assessed.
Conclusions: Use of the Accu-Chek Connect diabetes management system is associated with increased treatment satisfaction and improved glycemic control among individuals with insulin-treated diabetes. NCT02600845 ( www.clinicaltrials.gov ).
With almost 50 years of experience in the diabetes care space, our vision is to help people with diabetes everywhere in the world think less about their daily diabetes routine so they can experience true relief, day and night, no matter where they live. Together, with our partners, we are dedicated to advancing care through our integrated Personalised Diabetes Management (iPDM) solutions, broadening access, and fostering sustainable structures to drive optimal management of this chronic condition.
With our Accu-Chek and mySugr brands, we offer a broad portfolio of glucose monitoring, insulin delivery, and digital solutions to people with diabetes, caregivers and healthcare providers (HCPs), no matter where they are on their diabetes journey.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
IBM is a registered trademark of International Business Machines Corp. Intel and Pentium are registered trademarks of Intel Corporation. Windows, Windows Server and Windows Vista are registered trademarks of Microsoft Corporation.
For more information on how to use the Accu-Chek 360 diabetes management system software, click on the Help button in the top right hand corner of the software interface, or contact (insert affiliate contact information).
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. For any further information please contact the authorized local representative in your country.
With the integration of the Accu-Chek Insight insulin pump, Diabeloop and Roche offer people with diabetes the possibility to choose an automated and personalized management using a sleek-designed and pre-filled insulin cartridge pump.
In early 2021, Accu-Chek Insight users in Germany, Italy, Spain, Switzerland, and the Netherlands will be able to operate the insulin pump in loop mode, within the DBLG1 System with Accu-Chek Insight insulin pump.
Diabeloop who announced, earlier this year, both the CE marking of DBL-hu (AID for Type 1 highly unstable diabetes) and the conclusion of an agreement with global healthcare leader Terumo, still pursues the expansion of its interoperable solution in Germany and France where reimbursement process is in progress.
March 26, 2024 - Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), has emerged as a significant advancement in diabetes technology over the last 50 years. Although commercial insulin pumps were introduced in the 1970s, widespread adoption didn't occur until the early 2000s, following the Diabetes Control and Complications Trial (DCCT) in the early 1990s. The DCCT emphasized the importance of intensive insulin therapy for meticulous glycemic control and preventing diabetes-related complications.
An insulin pump is a compact, wearable device that administers short-acting insulin in small increments every few minutes throughout the day and night. It can also provide additional doses of short-acting insulin with the press of a button, either during meals or to lower high blood glucose levels. Insulin pumps generally come in two types: traditional tubed and tubeless (Figure 1).
Approved in June 2018, the t:slim X2 insulin pump with Basal-IQ Technology from Tandem Diabetes Care is an advanced device designed to assist individuals with diabetes in managing their insulin therapy. It features an easy-to-use color touchscreen interface, like a smartphone, allowing users to navigate various menus and settings. Through wireless connectivity, the pump can be connected to compatible devices, such as automated insulin dosing software or continuous glucose monitoring (CGM) systems.
When used with the Dexcom G5 Mobile CGM or compatible iCGMs, the Basal-IQ Technology can suspend insulin delivery based on CGM sensor readings. This device utilizes predictive technologies to automate insulin delivery based on real-time glucose data, helping users maintain optimal glucose levels. The pump holds a reservoir or cartridge filled with insulin, delivered subcutaneously through a small cannula or tubing. Overall, the t:slim X2 insulin pump offers a user-friendly interface, wireless connectivity, and predictive technologies to enhance insulin therapy management for individuals with diabetes.
In January 2022, the Omnipod 5 automated insulin delivery (AID) system from Insulet gained FDA approval for individuals aged 6 and above with T1D, with a limited release, making it the initial tubeless AID system for individuals with T1D requiring both basal and mealtime insulin. This AID system was released to the market on August 1, 2022, and gained expanded approval on August 22, 2022, to include individuals aged 2 and above with T1D.
The Omnipod 5 is a fully integrated closed-loop automated insulin delivery (AID) system. It combines a wearable insulin delivery pod with a smartphone app, eliminating the need for a separate controller device. The Omnipod 5 also features SmartAdjust technology, activity features, a SmartBolus calculator, and a waterproof construction. It also offers advanced features and integration with the Dexcom G6 continuous glucose monitoring (CGM) system.
Approved in April 2023, The Medtronic MiniMed 780G System is an automated insulin delivery system that helps individuals aged 7 and older manage their diabetes. This system continuously monitors glucose levels, delivers insulin automatically, and adjusts the dosage as needed. It provides real-time glucose trend information, alerts, and alarms, allowing users to make informed decisions about their diabetes management.
Insulet's newest AID system, Omnipod GO, received FDA clearance in April 2023 and is currently commercializing its long-acting insulin delivery device. Designed for individuals with type 2 diabetes (T2D) aged 18 or older, Omnipod GO covers the basal-only insulin population. This device offers a discreet and tubeless design, eliminating the need for traditional insulin pump tubing. Users can easily apply and remove the device, providing convenience and flexibility in their daily activities. Omnipod GO is a standalone device that does not connect to any devices.
The Omnipod GO is a simplified version of the Omnipod system, comprising a wearable insulin delivery pod without the integrated closed-loop system or smartphone app. The Omnipod GO is designed to provide a more affordable and accessible option for individuals who may not require the advanced features of the Omnipod 5.
The Beta Bionics iLet ACE Pump and iLet Dosing Decision Software received FDA clearance in May 2023. This system, along with a compatible integrated continuous glucose monitor (iCGM), forms the iLet Bionic Pancreas. The iLet Bionic Pancreas is an automated insulin dosing (AID) system that utilizes an algorithm to determine and command insulin delivery.
Approved in August 2023, the Roche Accu-Chek Solo Micropump System, developed by Roche Diabetes Care, offers individuals with diabetes a convenient and flexible way to manage their insulin therapy. The Accu-Chek Solo Micropump System is a tubeless patch pump that integrates the insulin pump, infusion set, and reservoir into a single device, simplifying the entire system.
The system delivers insulin subcutaneously through a small cannula inserted into the skin and allows for customizable basal rates and bolus doses to meet individual insulin needs. The Accu-Chek Solo Micropump System includes user-friendly features such as an integrated and illuminated Accu-Chek Guide test strip port for blood glucose monitoring. It also features a clinically proven bolus advisor to calculate insulin doses. Users can set up to five different basal rate profiles, providing flexibility in insulin delivery based on daily needs. Additionally, the system offers an MDI mode, allowing users to temporarily switch to using a pen for insulin delivery without losing important data. 152ee80cbc